Vexev
About
About Vexev
Vexev builds autonomous vascular-imaging systems around robotics, ultrasound and computational blood-flow analysis. Its lead platform, VxWave, guides an ultrasound probe and reconstructs three-dimensional vascular scans so trained non-specialist staff can acquire standardized images. The first clinical focus is upper-limb imaging for dialysis vascular access.
VxWave remains investigational and is not cleared for commercial sale. A multisite study with U.S. Renal Care reported a 94% scan-success rate in routine dialysis-clinic workflows. Vexev's August 2026 financing brings disclosed funding to $19 million and supports FDA 510(k) work, manufacturing scale-up and U.S. commercialization.
Articles
Funding
- 2026-08-06 - Funding round - $6M - Vexev raises $6 million for VxWave U.S. commercialization
Vexev raised $6 million, bringing total funding to $19 million, to advance regulatory work, manufacturing scale-up and U.S. commercialization of VxWave. - source: prnewswire.com
Investors
- Alumni Ventures - Participant - VC - 1 funding event - first seen 2026-08-06
- Bioshore Ventures - Participant - VC - 1 funding event - first seen 2026-08-06
- Blackbird Ventures - Participant - VC - 1 funding event - first seen 2026-08-06
- Horizon - Participant - Unknown - 1 funding event - first seen 2026-08-06
- Neotribe Ventures - Participant - VC - 1 funding event - first seen 2026-08-06
- Startmate - Participant - Unknown - 1 funding event - first seen 2026-08-06
- TEN13 - Participant - Unknown - 1 funding event - first seen 2026-08-06
- TreeArc Investment Group - Participant - Unknown - 1 funding event - first seen 2026-08-06
Team
- John Carroll - Co-founder and Chief Executive Officer - Leads Vexev strategy, clinical validation and U.S. commercialization.
- Eamonn Colley - Co-founder - Co-developed the robotics and imaging foundation behind VxWave.
Timeline
Events
- 2026-08-06 - Funding - Vexev raises $6 million for VxWave U.S. commercialization
VxWave combines robotics, AI and ultrasound to automate three-dimensional upper-limb vascular imaging, initially for dialysis vascular-access workflows. A multisite U.S. Renal Care study achieved a 94% scanning success rate when the investigational system was used by non-specialist staff. TreeArc Investment Group, TEN13, Bioshore Ventures and Alumni Ventures joined existing backers including Blackbird Ventures and Neotribe Ventures.
Source